首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal TRAF3IP2 Antibody

  • 中文名: TRAF3IP2抗体
  • 别    名: ACT1; CIKS; C6orf2; C6orf4; C6orf5; C6orf6; PSORS13
货号: IPDX07677
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/25-1/100 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/1000-1/2000 Human,Mouse,Rat

产品详情

参考文献

以下是关于TRAF3IP2抗体的3篇参考文献,包含文献名称、作者及摘要概述:

1. **"TRAF3IP2 mediates inflammatory responses by regulating IL-17 signaling in psoriasis"**

- **作者**: Lee E, et al. (2019)

- **摘要**: 本研究通过使用TRAF3IP2特异性抗体,揭示了其在银屑病中调控IL-17信号通路的作用。实验显示,阻断TRAF3IP2可显著减少角质形成细胞的炎症因子释放,提示其作为治疗靶点的潜力。

2. **"A novel monoclonal antibody targeting TRAF3IP2 attenuates autoimmune arthritis in murine models"**

- **作者**: Zhang Y, et al. (2021)

- **摘要**: 该研究开发了一种靶向TRAF3IP2的单克隆抗体,并在类风湿性关节炎小鼠模型中验证其疗效。结果显示,抗体能抑制TRAF3IP2与IL-17受体的相互作用,减轻关节炎症和骨质破坏。

3. **"TRAF3IP2-dependent signaling pathways in systemic lupus erythematosus: Insights from antibody-based inhibition"**

- **作者**: Gupta S, et al. (2020)

- **摘要**: 通过抗体阻断TRAF3IP2.研究发现其可下调系统性红斑狼疮(SLE)患者外周血单核细胞中NF-κB和AP-1的激活,减少促炎细胞因子产生,为SLE的免疫治疗提供新方向。

**注**:以上文献为示例,实际引用时需根据具体研究补充真实发表信息。建议通过PubMed或Web of Science以“TRAF3IP2 antibody”为关键词检索最新研究。

背景信息

The TRAF3IP2 (TRAF3 Interacting Protein 2) antibody is a tool used to study the TRAF3IP2 protein, a key adaptor molecule involved in inflammatory and immune signaling pathways. TRAF3IP2. also known as ACT1 or CIKS, interacts with TRAF proteins (TNF receptor-associated factors) to mediate signals from cytokine receptors, such as IL-17 receptors, and regulates activation of NF-κB and JNK pathways. Its role in modulating immune responses links it to autoimmune diseases like psoriasis, rheumatoid arthritis, and lupus, as well as cancer progression. Antibodies targeting TRAF3IP2 enable researchers to detect its expression, localization, and interactions in cells or tissues. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate TRAF3IP2’s involvement in disease mechanisms or therapeutic targeting. Studies using TRAF3IP2 antibodies have revealed its overexpression in certain cancers and its regulatory effects on pro-inflammatory cytokines, making it a potential biomarker or drug target. Validation of these antibodies often includes knockout controls to ensure specificity, as TRAF3IP2 shares functional domains with other signaling proteins. Overall, TRAF3IP2 antibodies are vital for dissecting its contributions to immune dysregulation and developing precision therapies.

客户数据及评论

折叠内容

大包装询价

×